Introduction Sexual health is an integral part of overall health. Sexual dysfunction can have a major impact on quality of life and psychosocial and emotional well-being. Aim To provide evidence-based, expert-opinion consensus guidelines for clinical management of sexual dysfunction in men. Methods An international consultation collaborating with major urologic and sexual medicine societies convened in Paris, July 2009. More than 190 multidisciplinary experts from 33 countries were assembled into 25 consultation committees. Committee members established scope and objectives for each chapter. Following an exhaustive review of available data and publications, committees developed evidence-based guidelines in each area. Main Outcome Measures New algorithms and guidelines for assessment and treatment of sexual dysfunctions were developed based on work of previous consultations and evidence from scientific literature published from 2003 to 2009. The Oxford system of evidence-based review was systematically applied. Expert opinion was based on systematic grading of medical literature, and cultural and ethical considerations. Results Algorithms, recommendations, and guidelines for sexual dysfunction in men are presented. These guidelines were developed in an evidence-based, patient-centered, multidisciplinary manner. It was felt that all sexual dysfunctions should be evaluated and managed following a uniform strategy, thus the International Consultation of Sexual Medicine (ICSM-5) developed a stepwise diagnostic and treatment algorithm for sexual dysfunction. The main goal of ICSM-5 is to unmask the underlying etiology and/or indicate appropriate treatment options according to men’s and women’s individual needs (patient-centered medicine) using the best available data from population-based research (evidence-based medicine). Specific evaluation, treatment guidelines, and algorithms were developed for every sexual dysfunction in men, including erectile dysfunction; disorders of libido, orgasm, and ejaculation; Peyronie’s disease; and priapism. Conclusions Sexual dysfunction in men represents a group of common medical conditions that need to be managed from a multidisciplinary perspective.

No abstract

Introduction UK primary care physicians are required to follow authoritative endorsed guidelines as part of their terms of service. The major influence on the management of erectile dysfunction in primary and secondary care between 1999 and 2007 has been Department of Health “guidance on good practice,” a non-evidence-based document, essentially defining patients who qualify for government-funded treatment. Aim To provide clinically based guidelines relevant to UK primary and secondary healthcare professionals in their daily practice. Methods A multidisciplinary panel of seven UK experts including two primary care physicians from the British Society for Sexual Medicine met for two full day meetings between September 2006 and April 2007, with each member allocated to disease areas related to their specialty. Feedback and approval of all sections between panel members was facilitated by the chairman. Source information was obtained from peer reviewed articles, meetings and presentations. Articles were chosen from electronically searching the Cochrane Library, Medline and Embase for randomized controlled clinical trials and graded according to level of evidence. Results Patient-reported sexual activity, satisfaction with sexual activity (Male Sexual Health Questionnaire), and treatment expectations; urologists' subjective assessment of the importance given by their patients to ED; the timing they propose for starting ED treatment. Results After the second full day meeting in January 2007, the final version was approved by panel members and made available for healthcare professions by download from http://www.bssm.org and from http://www.eguidelines.co.uk Conclusion A comprehensive evidence-based guideline has been developed that is highly relevant for primary and secondary care professionals enabling them to work within the unique requirements of the UK healthcare system.

OBJECTIVESTo compare treatment preference, efficacy, and tolerability of sildenafil citrate (sildenafil) and tadalafil for treating erectile dysfunction (ED) in men naïve to phosphodiesterase 5 (PDE5) inhibitor therapy. PATIENTS AND METHODSThis was an open-label, crossover study of sildenafil and tadalafil (taken as needed). After a 4-week baseline assessment, 367 men with ED (mean age 54 years) were randomized to receive sildenafil for 12 weeks followed by tadalafil for 12 weeks or vice versa (8-week dose optimization and 4-week assessment phases). During dose optimization, patients started taking 25-or 50-mg sildenafil or 10-mg tadalafil and could titrate to find their optimum dose (25-, 50-or 100-mg sildenafil; 10-or 20-mg tadalafil). After completing both 12-week periods, patients chose which treatment to continue during an 8-week extension. Efficacy was measured with the International Index of Erectile Function (IIEF) and Sexual Encounter Profile (SEP) diary. RESULTSOf the 291 men who completed both treatments, 85 (29%) chose sildenafil and 206 (71%) chose tadalafil ( P < 0.001) for the 8-week extension. The IIEF erectile function domain scores were 14.2 at baseline, 23.9 at endpoint on sildenafil, and 24.3 at endpoint on tadalafil ( P = 0.08, sildenafil vs tadalafil). The mean per patient percentage success scores for SEP2 (penetration) were: baseline (46%), sildenafil (post-baseline 82%) and tadalafil (post-baseline 85%; P = 0.06, sildenafil vs tadalafil), and for SEP3 (successful intercourse) were: baseline (19%), sildenafil (post-baseline 72%), and tadalafil (postbaseline 77%; P = 0.003, sildenafil vs tadalafil). The only treatment-emergent adverse events that were reported by > 5% of men were headache and flushing.

What's known on the subject? and What does the study add?• The management of patients with non-obstructive azoospermia (NOA) involves testicular sperm extraction (TESE or microdissection TESE) combined with intracytoplasmic sperm injection (ICSI). Sperm retrieval is successful in up to 50% of men with NOA; however, there is no single clinical finding or investigation that can accurately predict a positive outcome. Several studies have concluded that testicular biopsy is the best predictor of a successful TESE.• The present study shows that the strongest predictor of the success of TESE is when tubules with mature spermatozoa (Johnsen score Ն8) are found in the histopathology specimen, irrespective of the overall state of spermatogenesis. The findings suggest that a lower limit threshold value of 2% of tubules with spermatogenesis in the histopathology specimen will result in a positive sperm retrieval.• However, it is not practical to perform a diagnostic biopsy before TESE because this would mean that patients undergo two surgeries, which adds to the cost and increases the complications.• The diagnostic biopsy is best coupled with an initial TESE before starting the ICSI cycle. Based on the findings of the histopathology specimen, patients may be then offered a repeat TESE if more sperm is needed on the day of ovum pick-up and ICSI. Also, if the initial TESE was negative, the biopsy result will help in the decision to offer a repeat TESE. This regimen is more cost-effective because the ICSI cycle will be started only if adequate sperm is retrieved. Objective• To assess whether testicular histopathology can predict the outcome of testicular sperm extraction (TESE) in men with non-obstructive azoospermia (NOA) and therefore the role of preoperative diagnostic testis biopsy. Patients and Methods• The study comprised a retrospective analysis of 388 patients with azoospermia who were referred from 2005 to 2010.• Information collected included a clinical history and an examination including age and testicular size, serum follicle-stimulating hormone, two semen analyses and testicular histology collected at the time of surgical sperm retrieval (TESE or microdissection TESE). Results• In total, 388 patients with a mean (range) age of 37 (18-66) years were included in the present study.• Based on the history, clinical and laboratory findings, 112 patients had obstructive azoospermia and 276 patients had NOA. • All patients in the obstructed group had a positive sperm retrieval. The sperm retrieval rate for the NOA group was 50%. • An analysis of the results showed that the best predictor of a positive sperm retrieval was when tubules with mature spermatozoa were seen at biopsy, irrespective of the overall state of spermatogenesis (P < 0.001). Conclusions• The presence of tubules with spermatazoa on biospy is the best predictor of a positive surgical sperm retrieval in patients with NOA.• The diagnostic biopsy is best coupled with an initial TESE before starting the intracytoplasmic sperm injection (ICSI) cycle. Sexual ...